

Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000 • 510-236-8951(Fax)

SANGAMO BIOSCIENCES, INC. ANNOUNCES THE APPOINTMENT OF CARL O. PABO, PH.D. AS SENIOR VICE PRESIDENT AND CHIEF SCIENTIFIC OFFICER

Point Richmond, California – September 4, 2001 – Sangamo BioSciences, Inc., worldwide leader in the research and development of novel transcription factors for the regulation of gene expression, announced today the appointment of Carl O. Pabo, Ph.D., as Senior Vice President and Chief Scientific Officer.

Dr. Pabo is widely recognized for his pioneering research on the structure and energetic principles of protein-DNA recognition, the design and selection of zinc finger DNA binding proteins (ZFPs), and the application of engineered ZFPs in biological research. Over the span of his career, he and his colleagues have identified the fundamental determinants of DNA recognition by several DNA binding proteins. These observations have proven key to the engineering of ZFPs and their incorporation into ZFP transcription factors for the targeted regulation of gene expression.

Dr. Pabo comes to Sangamo after ten years as Professor of Biophysics and Structural Biology at the Massachusetts Institute of Technology and Investigator in the Howard Hughes Medical Institute. Prior to his faculty appointment at MIT, Dr. Pabo was a Professor in the Department of Molecular Biology and Genetics and the Department of Biophysics at the Johns Hopkins University School of Medicine. Dr. Pabo is a member of the American Academy of Arts and Sciences, the National Academy of Sciences, and has received numerous awards and honors including The Protein Society Young Investigator Award (1991) and the Pfizer Award in Enzyme Chemistry (1992). He received his Ph.D. in biochemistry in 1980 from Harvard University after working in the laboratory of Mark Ptashne, Ph.D., and a B.S. (summa cum laude) in biophysics and biochemistry from Yale University.

“We are honored and privileged to have Carl joining us as senior vice president and chief scientific officer,” said Edward Lanphier, Sangamo’s president and chief executive officer. “Carl has been a principal architect of our scientific strategy through his work as chairman of Sangamo’s scientific advisory board, and we now look forward to the opportunity to work with him on a day to day basis. Carl’s outstanding record of achievement, coupled with his extraordinary level of personal and professional integrity, will be a tremendous asset to Sangamo in the years to come.”

-more-

Sangamo BioSciences, Inc.
Point Richmond Tech Center
501 Canal Blvd., Suite A100
Richmond, CA 94804
510-970-6000 • 510-236-8951(Fax)

“I am thrilled with the opportunity to join Sangamo full-time,” said Carl Pabo. “The company has an incredibly enthusiastic and talented scientific staff. I have deep respect for the management team led by Edward Lanphier, and I have enjoyed working with Sangamo over the past two years as chairman of the scientific advisory board. I look forward to working closely with Casey Case, Ph.D., Sangamo’s vice president of research, and with Yen Choo, Ph.D., who has led an outstanding scientific team at Gendaq, recently acquired by Sangamo. I also would like to express my deepest respect and admiration for my predecessor, Alan Wolffe, Ph.D., who Sangamo tragically lost earlier this year. We remain deeply indebted for his enormous contributions during his time at the company.”

About Sangamo

Sangamo is focused on the research and development of novel transcription factors for the regulation of gene expression. Sangamo’s Universal Gene Recognition™ technology enables the engineering of a particular class of transcription factors known as zinc finger DNA-binding proteins, or ZFP TFs. By engineering ZFP TFs so that they can recognize a specific gene, Sangamo has created ZFP TFs that can control gene expression and, consequently, cell function. The company intends to establish Universal Gene Recognition as a widely used technology for commercial applications in pharmaceutical discovery, human therapeutics, clinical diagnostics, agriculture and industrial biotechnology. Over twenty leading pharmaceutical and biotechnology companies have utilized ZFP TFs. In addition, Sangamo is developing novel ZFP TF-based therapeutics for the treatment of cardiovascular disease. For more information about Sangamo, visit the company’s web site at www.sangamo.com.

Contact: Edward Lanphier
510-970-6000, 207

###